Bellicum Pharma (BLCM): Raising PT On Accelerated BPX-501 Approval - Piper Jaffray
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Bellicum Pharma (NASDAQ: BLCM) announced a strategy to pursue a rapid path of approval for BPX-501, the company's allogeneic T-cell add-back with an "off switch". The EMA has agreed data that an expanded BP-004 study could support approval under "exceptional circumstances" for pediatric patients in malignant and nonmalignant settings. The analyst e believes BPX-501 is a highly differentiated program and the broad ability to control cells is increasingly attractive in a CAR-T field that has suffered some safety concerns.
The company will also be advancing a CD19 targeting CAR-T with the CaspaCIDe "off-switch" which the analyst believes will be competitive.
Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating but rapid progress of BPX-501 towards approval pushes accelerated EU approval forward into 2018 resulting in a PT change from $25 to $31.
Shares of Bellicum Pharmaceuticals closed at $17.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FBR Capital Raises Price Target on HomeStreet (HMST) Following Record 3Q
- Netflix (NFLX) PT Raised to $140 at Guggenheim
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesPiper Jaffray, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!